U.S. Transthyretin Amyloidosis Treatment Market, By Type (Hereditary Transthyretin Amyloidosis (hATTR-CM) and Wild Type Amyloidosis), By Drug Type (Tafamidis, Diflunisal, Inotersen, Patisiran, Tolcapone, and Others), By Distribution Channel (Hospital Phar

U.S. Transthyretin Amyloidosis Treatment Market, By Type (Hereditary Transthyretin Amyloidosis (hATTR-CM) and Wild Type Amyloidosis), By Drug Type (Tafamidis, Diflunisal, Inotersen, Patisiran, Tolcapone, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Transthyretin amyloidosis is a rare, progressive, and fatal disorder caused by mutations in the transthyretin (TTR) gene. These mutations lead to deposition of abnormal TTR protein fibers known as amyloid in vital organs like heart, nerves, and gastrointestinal tract. The accumulation of amyloid fibrils in these organs progressively damages their structure and function. With no approved disease-modifying therapies available so far, ATTR amyloidosis was considered untreatable and fatal. However, recent advancements in understanding the disease pathogenesis along with approvals of novel therapies have provided new hope to patients. The U.S. transthyretin amyloidosis treatment market has witnessed significant growth due to these approval milestones.

Market Dynamics:

The U.S. transthyretin amyloidosis treatment market growth is driven by increasing disease awareness, approvals of novel disease-modifying therapies, and expansion of treatment landscape beyond symptom management. Factors such as longer life expectancy and improved diagnosis are also contributing to market growth. Despite the positive momentum, high treatment costs remain a key restraint. Infrastructure challenges in effective diagnosis also hamper market potential. However, ongoing clinical trials evaluating new treatment options and expansion of approval to different subtypes present lucrative opportunities. Partnerships between players to enhance access further boost the market outlook.

Key Features of the Study:

• This report provides in-depth analysis of the U.S. transthyretin amyloidosis treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• Key companies covered as a part of this study include Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc, GSK plc, Ionis Pharmaceuticals, Inc., SOM Innovation Biotech, S.L., Eidos Therapeutics, BridgeBio Pharma, Inc., Bristol-Myers Squibb Company, AstraZeneca, Acrotech Biopharma, and Attralus, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The U.S. transthyretin amyloidosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. transthyretin amyloidosis treatment market

Market Segmentation

• By Type Insights (Revenue, USD Mn, 2019 - 2031)
• Hereditary Transthyretin Amyloidosis (hATTR-CM)
• Wild Type Amyloidosis (wATTR-CM)
• By Drug Type Insights (Revenue, USD Mn, 2019 - 2031)
• Tafamidis
• Diflunisal
• Inotersen
• Patisiran
• Tolcapone
• Others
• By Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Key Players Insights
• Alnylam Pharmaceuticals, Inc.
• Pfizer, Inc.
• Prothena Corporation Plc
• GSK plc
• Ionis Pharmaceuticals, Inc.
• SOM Innovation Biotech, S.L.
• Eidos Therapeutics
• BridgeBio Pharma, Inc.
• Bristol-Myers Squibb Company
• AstraZeneca
• Acrotech Biopharma
• Attralus, Inc.